Focus: Charter Medical is a specialty pharmaceutical company headquartered in Winston-Salem, NC, focused on single-use devices across multiple therapeutic areas including neurology, cardiovascular, oncology, infectious diseases, and metabolic diseases.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Charter Medical offers stability through established products but presents limited career upside due to pipeline drought, extreme revenue concentration, and minimal hiring activity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product generating 71% of company revenue but facing imminent loss of exclusivity, creating existential business risk.
Help build intelligence for Charter Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Charter Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Small revenue contributor with 6-year patent window; minimal commercial impact but longer LOE timeline than CLOZARIL.
Post-patent generic product generating modest revenue; typical of mature, low-margin franchises.
Post-LOE niche product with minimal commercial value; indicative of portfolio density with legacy agents.
Post-LOE small-revenue generic; represents low-priority maintenance asset.
Post-LOE controlled substance with minimal commercial footprint; regulatory complexity without revenue justification.
Peak-cycle antiviral with earlier LOE date (2026) than SITAVIG; minimal reported spending.
Brand NDA approaching LOE in competitive cardiovascular space; no reported Part D spending.
Post-LOE SSRI generic in saturated market; no reported Part D spending.
Post-LOE SSRI generic; represents portfolio breadth without significant commercial momentum.
63 discontinued, 50 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+34 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo